CD8A and glioblastoma: Pharmacological inhibition of FAO, such as using etomoxir, has demonstrated the potential to reprogram the TME, promoting CD8+ T cell activation and improving the efficacy of immunotherapy in preclinical GBM models (Darwish et al., 2024; Tanase et al., 2022).